Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Lundbeck
|
| gptkbp:activities |
partial agonist at dopamine D2 receptors
partial agonist at serotonin 5-H T1 A receptors antagonist at serotonin 5-H T2 A receptors |
| gptkbp:affects |
metabolic syndrome
cardiovascular issues hyperlipidemia tardive dyskinesia diabetes risk increase |
| gptkbp:approves |
gptkb:legislation
gptkb:FDA gptkb:Japan gptkb:United_States |
| gptkbp:brand |
gptkb:Abilify_My_Cite
gptkb:Abilify |
| gptkbp:class |
atypical antipsychotic
dopamine system stabilizer |
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
hypersensitivity to aripiprazole
history of neuroleptic malignant syndrome severe depression with suicidal thoughts |
| gptkbp:dosage_form |
oral
injection |
| gptkbp:effective_date |
gptkb:2002
|
| gptkbp:form |
gptkb:tablet
oral solution injectable solution |
| https://www.w3.org/2000/01/rdf-schema#label |
Abilify
|
| gptkbp:ingredients |
gptkb:aripiprazole
|
| gptkbp:interacts_with |
antidepressants
antihypertensives CY P2 D6 inhibitors CY P3 A4 inhibitors |
| gptkbp:invention |
gptkb:2020
|
| gptkbp:is_available_on |
prescription medication
|
| gptkbp:is_used_for |
schizophrenia
bipolar disorder autism spectrum disorder major depressive disorder |
| gptkbp:manufacturer |
gptkb:Otsuka_Pharmaceutical
|
| gptkbp:marketed_as |
gptkb:Abilify_Maintena
gptkb:Aristada |
| gptkbp:origin |
gptkb:Japan
|
| gptkbp:previous_name |
gptkb:aripiprazole
|
| gptkbp:side_effect |
anxiety
fatigue headache nausea vomiting restlessness drowsiness insomnia constipation dry mouth weight gain |